首页> 外文OA文献 >Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
【2h】

Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples

机译:地西他滨对临床肿瘤样品中推定的抑癌基因FHIT,WWOX,FUS1和PTEN的免疫组织化学表达的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and phosphatase and tensin homolog (PTEN), immunohistochemistry scores from pre- and post-decitabine tumor biopsies (25 patients) were correlated with methylation of the long interspersed nuclear element-1 (LINE-1) repetitive DNA element (as a surrogate for global DNA methylation) and with tumor regression. Results With negative staining pre-decitabine (score = 0), the number of patients converting to positive staining post-decitabine was 1 of 1 for FHIT, 3 of 6 for WWOX, 2 of 3 for FUS1 and 1 of 10 for PTEN. In tumors with low pre-decitabine tumor suppressor gene scores (≤150), expression was higher post-treatment in 8 of 8 cases for FHIT (P = 0.014), 7 of 17 for WWOX (P = 0.0547), 7 of 12 for FUS1 (P = 0.0726), and 1 of 16 for PTEN (P = 0.2034). If FHIT, WWOX and FUS1 were considered together, median pre- versus post-decitabine scores were 60 versus 100 (P = 0.0002). Overall, tumor suppressor gene expression change did not correlate with LINE-1 demethylation, although tumors converting from negative to positive had a median decrease in LINE-1 methylation of 24%, compared to 6% in those not converting (P = 0.069). Five of 15 fully evaluable patients had reductions in tumor diameter (range 0.2% to 33.4%). Of these, three had simultaneous increases in three tumor suppressor genes (including the two patients with the greatest tumor regression) compared to 2 of 10 with tumor growth (P = 0.25). Conclusions In tumors with low tumor suppressor gene expression, decitabine may be associated with increased expression of the tumor suppressor genes FHIT, FUS1, and WWOX, but not PTEN.
机译:摘要背景由于抑癌基因的功能可能会因甲基化过度而丧失,因此我们评估了去甲基化地西他滨是否可以在临床上增加抑癌基因的表达。对于易碎的组氨酸三联体(FHIT),融合有肉瘤1(FUS1)和磷酸酶和肌腱蛋白同系物(PTEN)的含WW域的氧化还原酶(WWOX),进行了地西他滨前后肿瘤活检(25例)的免疫组化评分与长散布的核元素1(LINE-1)重复DNA元素的甲基化(作为整体DNA甲基化的替代物)和肿瘤消退相关。结果地卡他滨前染色为阴性(评分= 0),FHIT患者中转为阳性染色的人数为FHIT 1/1,WWOX 6/3,FUS1 3/2,PTEN 10/1。在地卡他滨前抑癌基因得分低(≤150)的肿瘤中,FHIT的8例中有8例(P = 0.014),WWOX的17例中有7例(P = 0.0547),12例中的7例中有更高的表达。 FUS1(P = 0.0726),以及PTEN的16之1(P = 0.2034)。如果同时考虑FHIT,WWOX和FUS1,则地卡他滨前后的中位数得分分别为60分和100分(P = 0.0002)。总体而言,肿瘤抑制基因的表达变化与LINE-1去甲基化无关,尽管从阴性转变为阳性的肿瘤中LINE-1甲基化的中值下降为24%,而未转变的肿瘤为6%(P = 0.069)。 15名可完全评估的患者中有5名肿瘤直径缩小(范围为0.2%至33.4%)。其中,三个肿瘤抑制基因同时增加(包括两名肿瘤消退最大的患者),而肿瘤生长的10个基因中有2个同时增加(P = 0.25)。结论在抑癌基因表达低的肿瘤中,地西他滨可能与抑癌基因FHIT,FUS1和WWOX的表达增加有关,而与PTEN无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号